Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00830180 · ClinicalTrials.gov registry record · Phase 2
Open Label Extension In Cancer Patients
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT00830180 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 41 participants.
The verdict
NCT00830180, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
To evaluate the safety and efficacy of anti-NGF AB in cancer patients with pain due to bone metastases who participated in the double-blind Study A4091003 and who wish to receive open-label therapy.
Interventions
- BIOLOGICAL Anti-NGF AB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2009-10-29 |
| Est. Completion | 2013-02-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00830180
The ClinicalTrials.gov registry entry for NCT00830180 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Anti-NGF AB is the first listed.
NCT00830180 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00830180 about?
NCT00830180 is a clinical study titled "Open Label Extension In Cancer Patients". To evaluate the safety and efficacy of anti-NGF AB in cancer patients with pain due to bone metastases who participated in the double-blind Study A4091003 and who wish to receive open-label therapy.
What is the current status of trial NCT00830180?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2009-10-29. Estimated completion is 2013-02-14.
What interventions are being tested in trial NCT00830180?
The interventions under investigation include: Anti-NGF AB (BIOLOGICAL).
Who is sponsoring clinical trial NCT00830180?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.